Last reviewed · How we verify
Placebo for oral CAB
This is a placebo, meaning it has no active ingredients and is used as a control in clinical trials.
This is a placebo, meaning it has no active ingredients and is used as a control in clinical trials. Used for Oral CAB treatment for phase 3 clinical trials.
At a glance
| Generic name | Placebo for oral CAB |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo is a substance or treatment that has no therapeutic effect but is used in clinical trials to compare the effects of a real treatment. In this case, the placebo is used in oral CAB clinical trials to serve as a control group.
Approved indications
- Oral CAB treatment for phase 3 clinical trials
Common side effects
Key clinical trials
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (PHASE2, PHASE3)
- Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention (NA)
- Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery (PHASE2)
- Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial (PHASE2)
- Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting (PHASE2)
- Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women (PHASE3)
- GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers (PHASE1)
- Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: